Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

SA-MTP: a structure-aware framework for multifunctional therapeutic peptide annotation.

Created on 04 Jul 2026

Authors

Wenping Yu, Zhewen Li, Wei Xu, Yu Zhao, Nan Sun

Published in

Briefings in bioinformatics. Volume 27. Issue 4. Jul 03, 2026.

Abstract

Therapeutic peptides show many biological activities and are now widely viewed as promising candidates for new drug development. Accurate functional annotation of therapeutic peptides is still difficult. This difficulty comes from their short sequence length, strong structural flexibility, and the presence of multiple biological functions within a single peptide.Here, we introduce Structure-Aware Multi-Label Therapeutic Peptide Predictor (SA-MTP), a structure-aware framework designed for multifunctional annotation of therapeutic peptides. SA-MTP combines pretrained protein language models with a graph attention network to capture sequence semantics and probabilistic structural features. Input-dependent structure-aware graphs are constructed to describe conformational variation, which is especially common in short peptides. Benchmarking experiments across 15 therapeutic function categories were conducted using datasets. The results show that SA-MTP achieves better performance than existing methods across several evaluation metrics, including accuracy, F1-score, and Matthews correlation coefficient.

PMID:
42398074
Bibliographic data and abstract were imported from PubMed on 04 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 4
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement